

1	Details of the person discharging managerial responsibilities							
a)	Name	<i>Michael Engsig</i>						
b)	Position	<i>Chief Executive Officer</i>						
2	Reason for notification							
a)	Initial notification/ Amendment	<i>Initial</i>						
3	Details of issuer							
a)	Name	<i>Nykode Therapeutics ASA</i>						
b)	LEI	<i>254900UKQHYZJD22017</i>						
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics ASA (ISIN: NO0010714785) as underlying</i>						
b)	Nature of the transaction	<i>Acceptance of a stock option</i>						
c)	Price(s) and volume(s)	<table> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>NOK 0</td><td>3,000,000</td></tr> </tbody> </table>	Price(s)	Volume(s)	NOK 0	3,000,000		
Price(s)	Volume(s)							
NOK 0	3,000,000							
d)	Aggregated information -Average price, aggregated volume and total amount	<table> <thead> <tr> <th>Price</th> <th>NOK 0</th> </tr> <tr> <th>Volume</th> <th>3,000,000</th> </tr> <tr> <th>Total amount</th> <th>NOK 0</th> </tr> </thead> </table>	Price	NOK 0	Volume	3,000,000	Total amount	NOK 0
Price	NOK 0							
Volume	3,000,000							
Total amount	NOK 0							
e)	Date of the transaction	<i>09.07.2025</i>						
f)	Place of the transaction	<i>Outside of trading venue</i>						

1	Details of the person discharging managerial responsibilities							
a)	Name	<i>Harald Gurvin</i>						
b)	Position	<i>Chief Financial Officer</i>						
2	Reason for notification							
a)	Initial notification/ Amendment	<i>Initial</i>						
3	Details of issuer							
a)	Name	<i>Nykode Therapeutics ASA</i>						
b)	LEI	<i>254900UKQHYZJD22017</i>						
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics ASA (ISIN: NO0010714785) as underlying</i>						
b)	Nature of the transaction	<i>Acceptance of a stock option</i>						
c)	Price(s) and volume(s)	<table> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>NOK 0</td><td>1,250,000</td></tr> </tbody> </table>	Price(s)	Volume(s)	NOK 0	1,250,000		
Price(s)	Volume(s)							
NOK 0	1,250,000							
d)	Aggregated information -Average price, aggregated volume and total amount	<table> <thead> <tr> <th>Price</th> <th>NOK 0</th> </tr> </thead> <tbody> <tr> <th>Volume</th> <th>1,250,000</th> </tr> <tr> <th>Total amount</th> <th>NOK 0</th> </tr> </tbody> </table>	Price	NOK 0	Volume	1,250,000	Total amount	NOK 0
Price	NOK 0							
Volume	1,250,000							
Total amount	NOK 0							
e)	Date of the transaction	<i>09.07.2025</i>						
f)	Place of the transaction	<i>Outside of trading venue</i>						

1	Details of the person discharging managerial responsibilities	
a)	Name	<i>Agnete B. Fredriksen</i>
b)	Position	<i>Chief Scientific Officer & Business Development</i>
2	Reason for notification	
a)	Initial notification/ Amendment	<i>Initial</i>
3	Details of issuer	
a)	Name	<i>Nykode Therapeutics ASA</i>
b)	LEI	<i>254900UKQHWYZJD22017</i>
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics ASA (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Acceptance of a stock option</i>
c)	Price(s) and volume(s)	<p>Price(s) NOK 0</p> <p>Volume 3,000,000</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p>Price NOK 0</p> <p>Volume 3,000,000</p> <p>Total amount NOK 0</p>
e)	Date of the transaction	<i>09.07.2025</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

1	Details of the person discharging managerial responsibilities	
a)	Name	<i>Ulrich Blaschke</i>
b)	Position	<i>Chief Technology Officer</i>
2	Reason for notification	
a)	Initial notification/ Amendment	<i>Initial</i>
3	Details of issuer	
a)	Name	<i>Nykode Therapeutics ASA</i>
b)	LEI	<i>254900UKQHYZJD22017</i>
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics ASA (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Acceptance of a stock option</i>
c)	Price(s) and volume(s)	<p>Price(s) NOK 0</p> <p>Volume 1,000,000</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p>Price NOK 0</p> <p>Volume 1,000,000</p> <p>Total amount NOK 0</p>
e)	Date of the transaction	<i>09.07.2025</i>
f)	Place of the transaction	<i>Outside of trading venue</i>